/C O R R E C T I O N -- Vector Sciences & Therapeutics/

Executive Summary

• Vector Sciences & Therapeutics entered into a three-year development and manufacturing agreement with MPP Group LLC to develop and manufacture pharmaceutical-grade peptides and drug delivery devices.
• The agreement provides Vector access to an FDA-registered, cGMP-compliant facility in Mequon, Wisconsin, avoiding approximately $6 million in capital expenditures for facility duplication.
• The partnership focuses on developing 22 novel shelf-stable peptide formulations (up to 24 months stability), including 14 peptides recently removed from the FDA Category 2 list, targeting the $80.8 billion peptide market.

Key Details

• Agreement Structure: Three-year development and manufacturing agreement with MPP Group LLC.
• Facility Access: Access to MPP’s FDA-registered, cGMP-compliant facility in Mequon, Wisconsin.
• Capital Savings: Avoidance of approximately $6 million in capital expenditure for facility duplication.
• Product Scope: Joint development of 22 novel peptide formulations designed to be shelf-stable for up to 24 months.
• Regulatory Context: 14 of the targeted peptides were recently removed by the FDA from the Category 2 list, making them eligible for compounding under physician supervision.
• Equipment Terms: Vector funds peptide-manufacturing equipment dedicated exclusively to its products, retains ownership, and has the right to take possession in the event of termination.
• Operational Timeline: Formulation development and initial manufacturing are scheduled to commence in May 2026.
• Intellectual Property: Purity and potency test methods developed jointly will be held as trade secrets for exclusive mutual use.
• Target Market: Pharmaceutical-grade products for physician-supervised use, supporting the build-out of Vector's distribution channel for its proprietary transdermal delivery technology.
• Listed Peptides: The release lists specific peptides under development, including BCP-157, TB-500, PT-141, Sermorelin, CJC-1295, Ipamorelin, MOTS-c, GHK-Cu, DSIP, KPV, Kisspeptin, Epitalon, Dihexa, Semaz (Heptapeptide), LL-37, Penealon, Selank, SS-31, Melanotan II, Ibutamoren, and NAD Mesylate.

Notable Quotes

• "Access to an FDA- drug registered, cGMP manufacturing facility is foundational for any company serious about delivering pharmaceutical-grade therapeutics. This agreement gives Vector that foundation right here in Wisconsin and positions the Company to bring the discipline of regulated drug manufacturing to its peptide portfolio from day one." -- Tommy Thompson, Chairman
• "This agreement gives Vector direct control over the equipment, the formulations, and the manufacturing process with a pharmaceutical-grade partner located in our own backyard. It is the foundation on which we will build our distribution channel for Vector's transdermal delivery technology." -- Bill Jackson, CEO
• "This agreement positions Vector to begin addressing those challenges by developing shelf-stable, pharmaceutical-grade formulations within a cGMP environment, an essential step toward our goal of enabling clinician-directed peptide delivery with improved site specificity." -- Dr. Brad Worthington, Chief Medical Officer